Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices 39155

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: July 7, 2000.

Time: 3:00 PM to 4:00 PM.

Agenda: To review and evaluate grant

applications.

Place: NIH, Rockledge 2, Bethesda, MD

20892 (Telephone Conference Call).

Contact Person: Philip Perkins, PhD,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 4148,

MSC 7804, Bethesda, MD 20892, (301) 435–

1718.

(Catalogue of Federal Domestic Assistance

Program Nos 93.306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333,

93.337, 93.393–93.396, 93.837–93.844,

93.846–93.878, 93.892, 93.893, National

Institutes of Health, HHS)

June 19, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–15937 Filed 6–22–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Office of the Director, National

Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the Peer

Review Oversight Group.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: Peer Review

Oversight Group.

Date: July 10–11, 2000.

Time: July 10, 2000, 8:30 AM to 5:00 PM.

Agenda: The discussions will focus on

peer review-related issues including, the use

of lay reviewers, structured review,

preliminary data, modular grant applications,

conflict of interest, Federal reimbursement

for compliance costs, and the status of

activities related to the implementation of

recommendations in the Regulatory Burden

Report.

Place: National Institutes of Health,

Building 60, 9000 Rockville Pike, Bethesda,

MD 20892.

Contact Person: Barbara Nolte, Program

Analyst, Office of Extramural Research,

National Institutes of Health, 9000 Rockville

Pike, Building 1, Room 252, Bethesda, MD

20892, 301–402–1058.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.14, Intramural Research

Training Award; 93.187, Undergraduate

Scholarship Program for Individuals from

Disadvantaged Backgrounds; 93.22, Clinical

Research Loan Repayment Program for

Individuals from Disadvantaged

Backgrounds; 93.232, Loan Repayment

Program for Research Generally; 93.39,

Academic Research Enhancement Award;

93.936, NIH Acquired Immunodeficiency

Syndrome Research Loan Repayment

Program, National Institutes of Health, HHS)

Dated: June 19, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–15938 Filed 6–22–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Federal Drug Testing Custody and

Control Form

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS.

ACTION: Notice of final form.

SUMMARY: The Substance Abuse and

Mental Health Services Administration

(SAMHSA) has revised the Federal Drug

Testing Custody and Control Form

(CCF). The current Federal CCF has a

July 31, 2000, expiration date. The

Office of Management and Budget

(OMB) has approved the use of the new

Federal CCF until June 30, 2003. OMB

approval of the new Federal CCF allows

Federal agencies and employers

regulated by the Department of

Transportation (DOT) to begin using the

new Federal CCF on August 1, 2000, for

their workplace drug testing programs.

EFFECTIVE DATE: August 1, 2000.

FOR FURTHER INFORMATION CONTACT:

Walter F. Vogl, Ph.D., Drug Testing

Section, Division of Workplace

Programs, CSAP, 5600 Fishers Lane,

Rockwall II, Suite 815, Rockville,

Maryland 20857, tel. (301) 443–6014,

fax (301) 443–3031, or email:

wvogl@samhsa.gov.

SUPPLEMENTARY INFORMATION:

Background

All urine specimens must be collected

using chain of custody procedures to

document the integrity and security of

the specimen from the time of collection

until receipt by the laboratory. To

ensure uniformity among all Federal

agency and federally regulated

workplace drug testing programs, the

use of an OMB approved Federal CCF is

required. Based on the experiences of

using the current Federal CCF for the

past several years, SAMHSA and DOT

initiated a joint effort to develop a new

Federal CCF that was easier to use and

more accurately reflected both the

collection process and how results were

reported by the drug testing laboratories.

This effort included scheduling two

public meetings attended by over 35

industry representatives who

recommended most of the changes to

the current Federal CCF. As a result of

these two meetings, SAMHSA

published a proposed revised Federal

CCF in a Federal Register notice (64 FR

61916) on November 15, 1999. A sample

of the proposed form was included in

that notice.

The first major proposed change was

to make the revised Federal CCF a sixpart form by eliminating the split

specimen copy. Since the split

specimen copy is used only when the

split specimen is tested (i.e., less than

approximately 5 percent of split

specimens are tested), it would be more

efficient to have the split specimen test

result reported on the original

laboratory copy (Copy 1). When the split

specimen is tested, the primary

laboratory would need to make a

photocopy of Copy 1 of the Federal CCF

and send it along with the split

specimen to the second laboratory.

Although this procedure requires the

primary laboratory to make a

photocopy, SAMHSA and DOT believe

the cost saving associated with not

including a separate split specimen

copy with each Federal CCF outweighs

the cost associated with the few times

that Copy 1 will need to be photocopied

by the primary laboratory. Additionally,

eliminating the split specimen copy will

help make any handwritten information

appear more legible on the later copies.

The second major proposed change

was to move the specimen bottle seal(s)/

label(s) from the right side of the form

to the bottom of Copy 1. This change

would permit overprinting information

on the form using standard width tractor

feed printers rather than requiring more

expensive wide carriage printers. In

addition, the storage and handling

requirements would be similar to other

documents since the overall size of the

new Federal CCF (including the tractor

feed strips) is essentially the same as a

standard sheet of paper.

The third major proposed change

involved simplifying the chain of

custody step by requiring the collector

to only sign the form once. SAMHSA

and DOT believe the current

requirement for the collector to sign the

39156 Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices

form three times can be replaced with

one signature because the certification

statement signed by the collector clearly

describes that the collector has

possession of the specimen from the

time the collector receives the specimen

from the donor until the collector

releases the specimen for shipment to

the laboratory.

The fourth major proposed change

was to provide a wider choice of terms

that a laboratory can use to report

specimen test results. The current form

uses the term ‘‘Test Not Performed’’ to

report any result other than a negative

or positive result. In fact, this term does

not always reflect the actual handling of

the specimen. SAMHSA and DOT

believe it is more appropriate to provide

a variety of terms on the Federal CCF

that accurately reflect the different

specimen test results that a laboratory

may report, such as, invalid result,

adulterated, substituted, or rejected for

testing.

The fifth major proposed change was

to include a new step on the original

laboratory copy (Copy 1) for reporting

the result for the split specimen (Bottle

B) since the split specimen copy was

eliminated. This change ensures that the

primary specimen and split specimen

laboratory test results are recorded on

the same copy that is provided to the

Medical Review Officer if the split

specimen is tested.

The sixth major proposed change was

to place the Medical Review Officer

(MRO) steps for both the primary and

split specimens on the MRO copy. This

change permits the MRO to record the

determination for both the primary

specimen and the split specimen (if

tested) on the same copy and to use this

copy to report results to the employer.

Other changes were considered to be

minor changes and were discussed as

each part of the proposed new form was

described in the November 15, 1999,

Federal Register notice.

Public Comments

SAMHSA received thirty comments

on the proposed changes from

laboratories, printing firms, employers,

organizations, and individuals. The

majority of comments supported the

proposed changes. All comments were

reviewed and taken into consideration

in preparing the new Federal CCF. The

substantive comments submitted and

SAMHSA’s and DOT’s response to those

comments are discussed below as each

step of the new Federal CCF is

described.

New Federal CCF

Appendix A is a sample of the new

Federal CCF.

General Changes

The new Federal CCF has the

following 5 copies: Copy 1—Laboratory

Copy, Copy 2—Medical Review Officer

Copy, Copy 3—Collector Copy, Copy

4—Employer Copy, and Copy 5—Donor

Copy. The reverse side of each copy

(i.e., Copy 1, Copy 2, Copy 3, Copy 4,

and Copy 5) must have the ‘‘Paperwork

Reduction Act Notice’’ statement. The

reverse side of Copy 5 must also have

the ‘‘Privacy Act Statement (for Federal

employees only)’’ and the ‘‘Instructions

for Completing the Federal Drug Testing

Custody and Control Form.’’ The

required statements and instructions for

completing the Federal CCF are

provided below.

The second laboratory copy was

eliminated from the proposed six-part

form when SAMHSA and DOT agreed to

permit a certified laboratory to transmit

a negative result to the Medical Review

Officer (MRO) electronically (e.g.,

facsimile, computer). The only time that

a hard copy of the Federal CCF must be

sent to the MRO is when the laboratory

is reporting either a positive for a

specific drug, adulterated, substituted,

rejected for testing, or invalid result. For

these relatively few non-negative

results, the laboratory is required to

make and send a photocopy of Copy 1

to the MRO even if an electronic report

was sent. SAMHSA and DOT believe

the additional cost saving associated

with not including the second

laboratory copy with each Federal CCF

outweighs the cost associated with the

few times that Copy 1 will need to be

photocopied by the primary laboratory.

Each copy of the new Federal CCF

will be on white paper. The proposed

changes had required using paper with

a different color border for the MRO,

collector, employer, and donor copies as

opposed to using a different color paper

for each of these copies as used for the

old form. Two comments supported

using paper with different color borders

while two comments opposed using

color borders. SAMHSA and DOT have

reevaluated the need to use either

different color paper or paper with

different color borders and believe that

using white paper for each copy is

sufficient to ensure that the copies will

be distributed as required. Additionally,

using white paper for all copies will

reduce the cost to assemble the form

and will make handwritten information

more legible on all copies.

The sequence of the copies for the

new Federal CCF was changed to

laboratory, MRO, collector, employer,

and donor. Three comments suggested

changing the sequence of the copies for

the proposed revised form because of

the concern with the legibility of the

information on the latter copies,

especially if a latter copy is needed to

replace a lost copy. SAMHSA and DOT

concur that legibility is a concern and

the best copies, beside the laboratory

copy, should be the MRO and collector

copies. If the employer and donor

copies are not entirely legible, the

information can be obtained from the

MRO or collector copies. In addition,

placing the donor copy last, gives the

donor the instructions for collecting the

urine specimen and completing the

Federal CCF. This may be useful if, at

a later time, the donor claims that the

collector did not follow the collection

procedure.

Copy 1—Laboratory Copy

Copy 1 has a one inch space at the top

of the page reserved for the following

items: the title ‘‘Federal Drug Testing

Custody and Control Form’’ must be

printed along the top edge, the OMB

Number must appear in the right hand

corner, name and street address of the

certified laboratory that will test the

specimen, a unique preprinted

specimen identification number, an

accession number after the specimen is

received by the laboratory, and any

other information (e.g., accounting code)

the laboratory or user of the form may

want to print on the form.

Step 1 is completed by the collector

or employer representative. A space is

provided for the name, address, and

identification number (if applicable) of

the employer and the name and address

of the MRO. The collector records the

donor’s social security number or other

employee identification number after

verifying the donor’s identity. The

collector marks the appropriate box to

indicate the reason for the test and the

appropriate box for the drug tests to be

performed. The collector records the

collection site address and the phone

and fax numbers where the collector can

be contacted.

Four comments recommended that

the we retain the same sequence for the

reasons for the test as on the current

CCF. SAMHSA and DOT concur with

that recommendation and changed the

sequence to coincide with that on the

current CCF. Three comments were

opposed to requiring the collector to

indicate the acronym of the Federal

agency for which the specimen was

being collected because the collector did

not always have that information. We

agree that that information is not always

known by the collector and deleted the

acronym from the new Federal CCF.

Step 2 is completed by the collector

after receiving the specimen from the

donor and measuring the temperature of

Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices 39157

the specimen. This step requires the

collector to mark the appropriate box to

indicate if the temperature of the

specimen was within the required

temperature range, whether it is a split

or single specimen collection, if no

specimen was collected, and if it was an

observed collection. A ‘‘Remarks’’ line

is provided when the collector is

required to provide a comment. One

comment suggested placing the box for

the split specimen collection before the

box for the single specimen collection.

SAMHSA and DOT agree with the

comment because the vast majority of

collections are split specimen

collections rather than single specimen

collections.

Step 3 directs the collector to affix the

seal(s)/label(s) to the specimen bottle(s),

to date the seal(s) after being placed on

the specimen bottle(s), to have the

donor initial the seal(s) after being

placed on the specimen bottle(s), and to

instruct the donor to complete step 5 on

the MRO copy (Copy 2). This is

essentially the same instruction that

appears on the current form.

Step 4 is a revised chain of custody

step that is initiated by the collector and

completed by the laboratory after the

specimen is accessioned by the

laboratory. This step requires the

collector to only sign the form once to

certify that the specimen was collected,

labeled, sealed, and released for

shipment to the laboratory in

accordance with Federal requirements.

SAMHSA and DOT believe that one

collector signature is sufficient to

document chain of custody from this

procedure. The collector is also required

to note the time of the collection, the

date of collection, and the specific name

of the delivery service to whom the

specimen is released for shipment to the

laboratory. This is the same information

that is required on the current Federal

CCF. Since there is no requirement for

delivery service personnel to document

chain of custody during transit because

they do not have access to the specimen

bottle(s) or the Federal CCF, chain of

custody annotations resume when the

shipping container/package is opened

and an individual at the laboratory has

access to the specimen bottle(s) and the

Federal CCF. We consider this

individual to be the accessioner, and he

or she is required to document the

condition of the primary specimen

bottle seal, sign the Federal CCF, print

his/her name, the date the specimen

was accessioned, and then to whom the

specimen was released. The entry for

the ‘‘Specimen Bottle(s) Released To’’

may include transfer to temporary

storage or transfer to another individual.

After this transfer, chain of custody for

the specimen bottle(s) is documented by

the laboratory using an internal chain of

custody form. Two comments suggested

deleting the requirement to record the

delivery service since it was mentioned

in the certification statement signed by

the collector and one commenter

suggested allowing preprinting a generic

term for the delivery service. SAMHSA

and DOT believe it is extremely

important to document that the collector

transferred the shipping container/

package to a specific delivery service. It

ensures that the collector knows that the

specimen must be directly transferred to

a specific delivery service rather than to

another individual or to temporary

storage.

Step 5(a) is completed by a certifying

scientist at the laboratory to document

the test result for the primary specimen.

The certifying scientist is required to

provide a signature, print his or her

name, and the date. This step has boxes

to allow the certifying scientist to easily

check whether the result is negative,

positive for a specific drug, rejected for

testing, adulterated, substituted, invalid

result, and/or dilute. One comment

suggested adding a box to check when

a specimen was dilute rather than

requiring a comment to written on the

‘‘Remarks’’ line. SAMHSA and DOT

concur with that recommendation and

added a box to check when a specimen

was dilute.

Step 5(b) is used by a certifying

scientist at the second certified

laboratory to document the test result

for the split specimen, if the split

specimen is tested. This step has a space

for the name and address of the second

laboratory, a certification statement,

appropriate boxes for the certifying

scientist to report the test result for the

split specimen, a signature line, a line

to print his or her name, and the date.

There were no comments submitted

regarding this step.

There must be two tamper-evident

specimen bottle seal(s)/label(s) located

in the bottom one and three-quarter inch

space of Copy 1. One label must have

the letter ‘‘A’’ on it to designate its use

for sealing and labeling the primary

specimen bottle and the other has the

letter ‘‘B’’ on it to designate its use for

sealing and labeling the split specimen

bottle. Each seal/label must have the

same specimen identification number

(either preprinted or overprinted before

use) that appears at the top of the form,

a place for the collector to annotate the

date of the collection, and a place for

the donor to initial each label after it is

placed on the specimen bottle. If a

single specimen collection procedure is

used, the ‘‘B’’ label is discarded by the

collector.

It is also the responsibility of the

supplier of the seals/labels to ensure

that they are tamper-evident. Tamperevident is defined as a seal/label that

cannot be removed from the specimen

bottle after 5 minutes contact with the

specimen bottle.

Three comments supported locating

the seals/labels at the bottom of the form

and three comments were opposed and

recommended leaving the seals/labels

attached to the side of the form. They

were concerned that placement of the

seals/labels at the bottom of the form

would jam the printers because of the

thickness of the form. SAMHSA and

DOT believe that reducing the number

of copies to 5 from 7 and ensuring that

a good quality tamper-evident seal/label

is properly placed on the form that the

seals/labels will not interfere with the

printing or overprinting process. There

are numerous examples of forms used

with labels placed directly onto the

forms that do not cause printing

problems and we fully expect that to be

the case when the new Federal CCF is

printed and used.

Copy 2—Medical Review Officer Copy

The Medical Review Officer copy is

the same format as Copy 1 except that

step 5(a) has been replace with step 5.

This step 5 on Copy 2 is completed by

the donor after the specimen bottle(s)

are sealed, initialed by the donor, and

dated. The donor is required to read the

certification statement, provide a

signature, printed name, date of

collection, daytime phone number,

evening phone number, and date of

birth. This information will be used by

the Medical Review Officer to contact

the donor for results that require donor

contact before making a determination.

Copy 3—Collector Copy

Exactly the same as Copy 2.

Copy 4—Employer Copy

Exactly the same as Copy 2.

Copy 5—Donor Copy

Exactly the same as Copy 2.

Paperwork Reduction Act Notice

The following Paperwork Reduction

Act Notice must appear on the back of

each copy (i.e, Copy 1, Copy 2, Copy 3,

Copy 4, and Copy5) of the Federal CCF:

Paperwork Reduction Act Notice (as required

by 5 CFR 1320.21)

Public reporting burden for this collection

of information, including the time for

reviewing instructions, gathering and

maintaining the data needed, and completing

and reviewing the collection of information

is estimated for each respondent to average:

5 minutes/donor; 4 minutes/collector; 3

39158 Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices

minutes/laboratory; and 3 minutes/Medical

Review Officer. Federal employees may send

comments regarding these burden estimates,

or any other aspect of this collection of

information, including suggestions for

reducing the burden, to the SAMHSA

Reports Clearance Officer, Paperwork

Reduction Project (0930–0158), Room 16–

105, Parklawn Building, 5600 Fishers Lane,

Rockville, MD 20857. An agency may not

conduct or sponsor, and a person is not

required to respond to, a collection of

information unless it displays a currently

valid OMB control number. The OMB control

number for this project is 0930–0158.

There were no comments submitted

regarding this Paperwork Reduction Act

Notice statement.

Privacy Act Statement

The following Privacy Act Statement

must appear on the back of the donor

copy (Copy 5):

Privacy Act Statement (For Federal

Employees Only)

Submission of the information on the

attached form is voluntary. However,

incomplete submission of the information,

refusal to provide a urine specimen, or

substitution or adulteration of a specimen

may result in delay or denial of your

application for employment/appointment or

may result in your removal from Federal

service or other disciplinary action.

The authority for obtaining the urine

specimen and identifying information

contained herein is Executive Order 12564

(‘‘Drug-Free Federal Workplace’’), 5 U.S.C.

§ 3301 (2), 5 U.S. C. § 7301 and Section 503

of Public Law 100–71, 5 U.S.C. § 7301 note.

Under provisions of Executive Order 12564

and U.S.C. 7301, test results may only be

disclosed to agency officials on a need-toknow basis. This may include the agency

Medical Review Officer, the administrator of

the Employee Assistance Program, and a

supervisor with authority to take adverse

personnel action. This information may also

be disclosed to a court where necessary to

defend against a challenge to an adverse

personnel action.

Submission of your SSN is not required by

law and is voluntary. Your refusal to furnish

your number will not result in the denial of

any right, benefit, or privilege provided by

law. Your SSN is solicited, pursuant to

Executive Order 9397, for purposes of

associating information in agency files

relating to you and for purposes of

identifying the specimen provided for

urinalysis testing for illegal drugs. If you

refuse to indicate your SSN, a substitute

number or other identifier will be assigned,

as required, to process the specimen.

In the event laboratory analysis determines

the presence of one or more illegal drugs in

the specimen you provide, you will be

contacted by an agency Medical Review

Officer (MRO). The MRO will determine

whether there is a legitimate medical

explanation for the drug(s) identified by

urinalysis.

There were no comments submitted

regarding this Privacy Act statement.

Instructions for Completing the Federal

CCF

The following instructions must

appear on the back of the donor copy

(Copy 5):

Instructions for Completing the Federal Drug

Testing Custody and Control Form

A. Collector ensures that the name and

address of the drug testing laboratory appear

on the top of the CCF and the Specimen I.D.

number on the top of the CCF matches the

Specimen I.D. number on the labels/seals.

B. Collector provides the required

information in STEP 1 on the CCF. The

collector provides a remark in STEP 2 if the

donor refuses to provide his/her SSN or

Employee I.D. number.

C. Collector gives a collection container to

the donor for providing a specimen.

D. After the donor gives the specimen to

the collector, the collector checks the

temperature of specimen within 4 minutes

and marks the appropriate temperature box

in STEP 2 on the CCF. The collector provides

a remark if the temperature is outside the

acceptable range.

E. Collector checks the split or single

specimen collection box. If no specimen is

collected, that box is checked and a remark

is provided. If it is an observed collection,

that box is checked and a remark is provided.

If no specimen is collected, Copy 1 is

discarded and the remaining copies are

distributed as required.

F. Donor watches the collector pouring the

specimen from the collection container into

the specimen bottle(s), placing the cap(s) on

the specimen bottle(s), and affixing the

label(s)/seal(s) on the specimen bottle(s).

G. Collector dates the specimen bottle

label(s) after they are placed on the specimen

bottle(s).

H. Donor initials the specimen bottle

label(s) after the label(s) have been placed on

the specimen bottle(s).

I. Collector turns to Copy 2 (MRO Copy)

and instructs the donor to read the

certification statement in STEP 5 and to sign,

print name, date, provide phone numbers,

and date of birth after reading the

certification statement. If the donor refuses to

sign the certification statement, the collector

provides a remark in STEP 2 on Copy 1.

J. Collector completes STEP 4 (i.e.,

provides signature, printed name, date, time

of collection, and name of delivery service),

immediately places the sealed specimen

bottle(s) and Copy 1 of the CCF in a leakproof plastic bag, releases specimen package

to the delivery service, and distributes the

other copies as required.

List of Acceptable Modifications

SAMHSA recognizes that different

hardware and software are used to

prepare and print forms and this will

create minor differences in the

appearance between forms. The

following is a list of acceptable

differences and modifications when

printing the Federal CCF:

(1) The OMB number may appear

either vertically or horizontally in the

upper right hand corner of the form.

(2) The name and address of the

testing laboratory and the unique

specimen identification number at the

top of the form and on the specimen

bottle seal(s)/label(s) may be printed

during the original printing and form

assembly process or added by

‘‘overprinting’’ after the form is

assembled.

(3) Preprinting and/or overprinting

the employer name and address, MRO

name and address, and collection site

information is permitted.

(4) The spaces for the employer name

and address, MRO name and address,

and the collection site address may have

lines.

(5) The unique specimen

identification number at the top of the

form and on the tamper-evident seal(s)/

label(s) may be either a bar code with

an associated human readable number

or only a human readable number.

(6) A laboratory does not need to

assign and record a separate laboratory

accession number in the one inch space

at the top of the form if it uses the

unique specimen identification number

to track the specimen after receipt.

When this is the case, the form may be

printed without the words ‘‘LAB

ACCESSION NO.’’ appearing on the top

of the form.

(7) The size of each ‘‘check’’ box may

vary slightly.

(8) The font size and style used for

letters may vary to enhance readability.

(9) The ‘‘exact’’ location for each item

on the printed form may vary slightly

from the location indicated on the

sample form provided in Appendix A.

(10) The data entry/information fields

may be highlighted using different

colors to show where the collector,

donor, and laboratory would be

providing information. The colors used

to highlight the fields may be different

for different fields, but must not prevent

making clear facsimiles and photocopies

of the information that is printed or

handwritten in these fields.

(11) The space for the donor’s SSN or

Employee I.D. No. may have combs,

boxes, or a single line.

(12) The legend at the bottom of

copies 2 through 5 may be printed using

different colors or a different color

stripe may be printed at the bottom of

copies 2 through 5. To ensure

consistency and correct distribution of

the copies, if different color stripes or

legends are used at the bottom of each

copy, the following colors must be used:

MRO copy—pink, Collector copy—

yellow, Employer copy—blue, Donor

copy—green.

(13) A reference mark(s) may be used

to position the form in a printer to

overprint information in the correct

Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices 39159

location or to optically scan the

information in the various fields.

(14) The size of the two tamperevident seals/labels may vary, but must

be placed within the space provided at

the bottom of Copy 1.

(15) The color of the preprinted

information on the ‘‘A’’ specimen bottle

tamper-evident seal/label may be

different than the color of the preprinted

information on the ‘‘B’’ specimen bottle

tamper-evident seal/label.

Availability of Federal CCF

The new Federal CCF is available on

the SAMHSA website (www.health.org/

workpl.htm) as an electronic ‘‘.pdf’’ file

that can be opened, saved, and printed.

Use of Expired Federal CCF

SAMHSA and DOT recognize that

there may be a large supply of old forms

at collection sites after the August 1,

2000, implementation date for the new

Federal CCF. To avoid discarding these

forms, OMB is permitting the use of the

old Federal CCF until supplies are

exhausted, but not to be used beyond

July 31, 2001. After that date, remaining

copies of the old Federal CCF should be

destroyed.

Richard Kopanda,

Executive Officer, Substance Abuse and

Mental Health Services Administration.

BILLING CODE 4162–20–P

39160 Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices

Appendix A

Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices 39161

Paperwork Reduction Act Notice (As

Required by 5 CFR 1320.21)

Public reporting burden for this collection

of information, including the time for

reviewing instructions, gathering and

maintaining the data needed, and completing

and reviewing the collection of information

is estimated for each respondent to average:

5 minutes/donor; 4 minutes/collector; 3

minutes/laboratory; and 3 minutes/Medical

Review Officer. Federal employees may send

comments regarding these burden estimates,

or any other aspect of this collection of

information, including suggestions for

reducing the burden, to the SAMHSA

Reports Clearance Officer, Paperwork

Reduction Project (0930–0158), Room 16–

105, Parklawn Building, 5600 Fishers Lane,

Rockville, MD 20857. An agency may not

conduct or sponsor, and a person is not

required to respond to, a collection of

information unless it displays a currently

valid OMB control number. The OMB control

number for this project is 0930–0158.

39162 Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices

Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices 39163

Paperwork Reduction Act Notice (As

Required by 5 CFR 1320.21)

Public reporting burden for this collection

of information, including the time for

reviewing instructions, gathering and

maintaining the data needed, and completing

and reviewing the collection of information

is estimated for each respondent to average:

5 minutes/donor; 4 minutes/collector; 3

minutes/laboratory; and 3 minutes/Medical

Review Officer. Federal employees may send

comments regarding these burden estimates,

or any other aspect of this collection of

information, including suggestions for

reducing the burden, to the SAMHSA

Reports Clearance Officer, Paperwork

Reduction Project (0930–0158), Room 16–

105, Parklawn Building, 5600 Fishers Lane,

Rockville, MD 20857. An agency may not

conduct or sponsor, and a person is not

required to respond to, a collection of

information unless it displays a currently

valid OMB control number. The OMB control

number for this project is 0930–0158.

39164 Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices

Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices 39165

Paperwork Reduction Act Notice (As

Required by 5 CFR 1320.21)

Public reporting burden for this collection

of information, including the time for

reviewing instructions, gathering and

maintaining the data needed, and completing

and reviewing the collection of information

is estimated for each respondent to average:

5 minutes/donor; 4 minutes/collector; 3

minutes/laboratory; and 3 minutes/Medical

Review Officer. Federal employees may send

comments regarding these burden estimates,

or any other aspect of this collection of

information, including suggestions for

reducing the burden, to the SAMHSA

Reports Clearance Officer, Paperwork

Reduction Project (0930–0158), Room 16–

105, Parklawn Building, 5600 Fishers Lane,

Rockville, MD 20857. An agency may not

conduct or sponsor, and a person is not

required to respond to, a collection of

information unless it displays a currently

valid OMB control number. The OMB control

number for this project is 0930–0158.

39166 Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices

Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices 39167

Paperwork Reduction Act Notice (As

Required by 5 CFR 1320.21)

Public reporting burden for this collection

of information, including the time for

reviewing instructions, gathering and

maintaining the data needed, and completing

and reviewing the collection of information

is estimated for each respondent to average:

5 minutes/donor; 4 minutes/collector; 3

minutes/laboratory; and 3 minutes/Medical

Review Officer. Federal employees may send

comments regarding these burden estimates,

or any other aspect of this collection of

information, including suggestions for

reducing the burden, to the SAMHSA

Reports Clearance Officer, Paperwork

Reduction Project (0930–0158), Room 16–

105, Parklawn Building, 5600 Fishers Lane,

Rockville, MD 20857. An agency may not

conduct or sponsor, and a person is not

required to respond to, a collection of

information unless it displays a currently

valid OMB control number. The OMB control

number for this project is 0930–0158.

39168 Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices

BILLING CODE 4162–20–C

Federal Register / Vol. 65, No. 122 / Friday, June 23, 2000 / Notices 39169

Instructions for Completing the Federal Drug

Testing Custody and Control Form

A. Collector ensures that the name and

address of the drug testing laboratory appear

on the top of the CCF and the Specimen I.D.

number on the top of the CCF matches the

Specimen I.D. number on the labels/seals.

B. Collector provides the required

information in STEP 1 on the CCF. The

collector provides a remark in STEP 2 if the

donor refuses to provide his/her SSN or

Employee I.D. number.

C. Collector gives a collection container to

the donor for providing a specimen.

D. After the donor gives the specimen to

the collector, the collector checks the

temperature of specimen within 4 minutes

and marks the appropriate temperature box

in STEP 2 on the CCF. The collector provides

a remark if the temperature is outside the

acceptable range.

E. Collector checks the split or single

specimen collection box. If no specimen is

collected, that box is checked and a remark

is provided. If it is an observed collection,

that box is checked and a remark is provided.

If no specimen is collected, Copy 1 is

discarded and the remaining copies are

distributed as required.

F. Donor watches the collector pouring the

specimen from the collection container into

the specimen bottle(s), placing the cap(s) on

the specimen bottle(s), and affixing the

label(s)/seal(s) on the specimen bottle(s).

G. Collector dates the specimen bottle

label(s) after they are placed on the specimen

bottle(s).

H. Donor initials the specimen bottle

label(s) after the label(s) have been placed on

the specimen bottle(s).

I. Collector turns to Copy 2 (MRO Copy)

and instructs the donor to read the

certification statement in STEP 5 and to sign,

print name, date, provide phone numbers,

and date of birth after reading the

certification statement. If the donor refuses to

sign the certification statement, the collector

provides a remark in STEP 2 on Copy 1.

J. Collector completes STEP 4 (i.e.,

provides signature, printed name, date, time

of collection, and name of delivery service),

immediately places the sealed specimen

bottle(s) and Copy 1 of the CCF in a leakproof plastic bag, releases specimen package

to the delivery service, and distributes the

other copies as required.

Privacy Act Statement: (For Federal

Employees Only)

Submission of the information on the

attached form is voluntary. However,

incomplete submission of the information,

refusal to provide a urine specimen, or

substitution or adulteration of a specimen

may result in delay or denial of your

application for employment/appointment or

may result in removal from the Federal

service or other disciplinary action.

The authority for obtaining the urine

specimen and identifying information

contained herein is Executive Order 12564

(‘‘Drug-Free Federal Workplace’’), 5 U.S.C.

§ 3301 (2), 5 U.S.C. § 7301, and Section 503

of Public Law 100–71, 5 U.S.C. § 7301 note.

Under provisions of Executive Order 12564

and 5 U.S.C. 7301, test results may only be

disclosed to agency officials on a need-toknow basis. This may include the agency

Medical Review Officer, the administrator of

the Employee Assistance Program, and a

supervisor with authority to take adverse

personnel action. This information may also

be disclosed to a court where necessary to

defend against a challenge to an adverse

personnel action.

Submission of your SSN is not required by

law and is voluntary. Your refusal to furnish

your number will not result in the denial of

any right, benefit, or privilege provided by

law. Your SSN is solicited, pursuant to

Executive Order 9397, for purposes of

associating information in agency files

relating to you and for purposes of

identifying the specimen provided for

urinalysis testing for illegal drugs. If you

refuse to indicate your SSN, a substitute

number or other identifier will be assigned,

as required, to process the specimen.

In the event laboratory analysis determines

the presence of one or more illegal drugs in

the specimen you provide, you will be

contacted by an agency Medical Review

Officer (MRO). The MRO will determine

whether there is a legitimate medical

explanation for the drug(s) identified by

urinalysis.

Paperwork Reduction Act Notice (as

Required by 5 CFR 1320.21)

Public reporting burden for this collection

of information, including the time for

reviewing instructions, gathering and

maintaining the data needed, and completing

and reviewing the collection of information

is estimated for each respondent to average:

5 minutes/donor; 4 minutes/collector; 3

minutes/laboratory; and 3 minutes/Medical

Review Officer. Federal employees may send

comments regarding these burden estimates,

or any other aspect of this collection of

information, including suggestions for

reducing the burden, to the SAMHSA

Reports Clearance Officer, Paperwork

Reduction Project (0930–0158), Room 16–

105, Parklawn Building, 5600 Fishers Lane,

Rockville, MD 20857. An agency may not

conduct or sponsor, and a person is not

required to respond to, a collection of

information unless it displays a currently

valid OMB control number. The OMB control

number for this project is 0930–0158.

[FR Doc. 00–15889 Filed 6–22–00; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. FR–4557–N–25]

Federal Property Suitable as Facilities

To Assist the Homeless

AGENCY: Office of the Assistant

Secretary for Community Planning and

Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies

unutilized, underutilized, excess, and

surplus Federal property reviewed by

HUD for suitability for possible use to

assist the homeless.

FOR FURTHER INFORMATION CONTACT:

Clifford Taffet, room 7266, Department

of Housing and Urban Development,

451 Seventh Street SW., Washington,

DC 20410; telephone(202) 708–1234;

TTY number for the hearing- and

speech-impaired (202) 708–2565 (these

telephone numbers are not toll-free), or

call the toll-free Title V information line

at 1–800–927–7588.

SUPPLEMENTARY INFORMATION: In

accordance with 24 CFR part 581 and

section 501 of the Stewart B. McKinney

Homeless Assistance Act (42 U.S.C.

11411), as amended, HUD is publishing

this Notice to identify Federal buildings

and other real property that HUD has

reviewed for suitability for use to assist

the homeless. The properties were

reviewed using information provided to

HUD by Federal landholding agencies

regarding unutilized and underutilized

buildings and real property controlled

by such agencies or by GSA regarding

its inventory of excess or surplus

Federal property. This Notice is also

published in order to comply with the

December 12, 1988 Court Order in

National Coalition for the Homeless v.

Veterans Administration, No. 88–2503–

OG (D.D.C.).

Properties reviewed are listed in this

Notice according to the following

categories: Suitable/available, suitable/

unavailable, suitable/to be excess, and

unsuitable. The properties listed in the

three suitable categories have been

reviewed by the landholding agencies,

and each agency has transmitted to

HUD: (1) Its intention to make the

property available for use as assist the

homeless, (2) its intention to declare the

property excess to the agency’s needs, or

(3) a statement of the reasons that the

property cannot be declared excess or

made available for use as facilities to

assist the homeless.

Properties listed as suitable/available

will be available exclusively for

homeless use for a period of 60 days

from the date of this Notice. Homeless

assistance providers interested in any

such property should send a written

expression of interest to HHS, addressed

to Brian Rooney, Division of property

Management, Program Support Center,

HHS, room 5B-41, 5600 Fishers Lane,

Rockville, MD 20857; (301) 443–2265.

(This is not a toll-free number.) HHS

will mail to the interested provider an

application packet, which will include

instructions for completing the

application. In order to maximize the

opportunity to utilize a suitable

property, providers should submit their

written expressions of interest as soon